Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: A randomized, double-blind, placebo-controlled clinical trial

Archives of Surgery

Volumn 141, Issue 2, 2006, Pages 150-153

  Orozco, Héctor ^a   Arch, Jorge ^a   Medina Franco, Heriberto ^a   Pantoja, Juan P ^a   González, Quintín H ^a   Vilatoba, Mario ^a   Hinojosa, Carlos ^a   Vargas Vorackova, Florencia ^a   Sifuentes Osornio, José ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; METRONIDAZOLE; OFLOXACIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CELL COUNT; BRAIN DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; LIVER FAILURE; LUNG EMBOLISM; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PERITONITIS; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; STATISTICAL SIGNIFICANCE; TERTIARY HEALTH CARE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CEFTRIAXONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LENGTH OF STAY; MALE; METRONIDAZOLE; MIDDLE AGED; PERITONITIS; RECOMBINANT PROTEINS; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33244495095     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.141.2.150     Document Type: Article

References (28)

1. Nelson S, Bagby GJ. Granulocyte colony-stimulating factor and modulation of inflammatory cells in sepsis. Clin Chest Med. 1996;17:319-332.
2. Weisbart RH, Gasson JC, Golde DW. Colony-stimulating factors and host defense. Ann Intern Med. 1989;110:297-303.
3. Austin OM, Redmond HP, Watson WG, Cunney RJ, Grace PA, Bouchier-Hayes D. The beneficial effects of immunostimulation in posttraumatic sepsis. J Surg Res. 1995;59:446-449.
4. Engelhard M, Brittinger G. Clinical relevance of granulocyte-macrophage colony-stimulating factor. Semin Oncol. 1994;21:1-4.
5. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery. 2000;127:117-126.
6. Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL. Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J. 2001;15:879-892.
7. Presneill JJ, Waring PM, Layton JE, et al. Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: relation to disease severity, multiple organ dysfunction, and mortality. Crit Care Med. 2000;28:2344-2354.
8. Williams MA, Withington S, Newland AC, Kelsey SM. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J Infect Dis. 1998;178:1421-1433.
9. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomized placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet. 1997;350:855-859.
10. Barsig J, Bundschuh DS, Hartung T, Bauhofer A, Sauer A, Wendel A. Control of fecal peritoneal infection in mice by colony-stimulating factors. J Infect Dis. 1996;174:790-799.
11. Davis KA, Fabian TC, Ragsdale DN, Trenthem LL, Croce MA, Proctor KG. Granulocyte colony-stimulating factor and neutrophil-related changes in local host defense during recovery from shock and intra-abdominal sepsis. Surgery. 1999;126:305-313.
12. Feterowski C, Weighardt H, Emmanuilidis K, Hartung T, Holzmann B. Immune protection against septic peritonitis in endotoxin-primed mice is related to reduced neutrophil apoptosis. Eur J Immunol. 2001;31:1268-1277.
13. Gennari R, Alexander JW, Gianotti L, Eaves-Pyles T, Hartmann S. Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance. Ann Surg. 1994;220:68-76.
14. Zhang P, Bagby GJ, Stoltz DA, Summer WR, Nelson S. Enhancement of peritoneal leukocyte function by granulocyte colony-stimulating factor in rats with abdominal sepsis. Crit Care Med. 1998;26:315-321.
15. Brauner A, Hylander B, Lu Y. Granulocyte stimulating factor in patients on peritoneal dialysis and LPS stimulated peripheral blood mononuclear cells. Inflammation. 1998;22:393-401.
16. Garcia-Gonzalez M, Boixeda D, Herrero D, Burgaleta C. Effect of granulocyte-macrophage colony-stimulating factor on leukocyte function in cirrhosis. Gastroenterology. 1993;105:527-531.
17. Bohnen JM, Mustard RA, Schouten BD. Steroids, APACHE II score, and the outcome of abdominal infection. Arch Surg. 1994;129:33-37.
18. Bohnen JM, Mustard RA, Oxholm SE, Schouten BD. APACHE II score and abdominal sepsis: a prospective study. Arch Surg. 1988;123:225-229.
19. Price J, Ekleberry A, Grover A, et al. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med. 1999;27:2118-2124.
20. Saionji K, Hamada T, Higurashi H, et al. Plasma macrophage colony-stimulating factor, granulocyte macrophage colony-stimulating factor and granulocyte colony-stimulating factor levels in continuous ambulatory peritoneal dialysis patients [in Japanese]. Rinsho Byori. 1997;45:493-497.
21. Barthlen W, Zantl N, Pfeffer K, Heidecke CD, Holzmann B, Stadler J. Impact of experimental peritonitis on bone marrow cell function. Surgery. 1999;126:41-47.
22. Metcalf D, Robb L, Dunn AR, Mifsud S, Di Rago L. Role of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in the development of an acute neutrophil inflammatory response in mice. Blood. 1996;88:3755-3764.
23. Pistoia V. Granulocyte-macrophage colony stimulating factor (GM-CSF); sources, targets and mechanism of action. Leukemia. 1991;5(suppl 1):114-118.
24. Toda H, Murata A, Oka Y, et al. Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. Blood. 1994;83:2893-2898.
25. Bilgin K, Yaramis A, Haspolat K, Tas MA, Gunbey S, Derman O. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics. 2001;107:36-41.
26. Bodey GP, Anaissie E, Gutterman J, Vadhan-Raj S. Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. Eur J Clin Microbiol Infect Dis. 1994;13(suppl 2):S18-S22.
27. Dierdorf R, Kreuter U, Jones TC. A role for granulocyte-macrophage colony-stimulating factor (GM-CSF) in the treatment of neutropenic patients with pneumonia. Braz J Infect Dis. 1997;1:68-76.
28. Root RK, Dale DC. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis. 1999;179(suppl 2):S342-S352.